

April 18, 2005

Teikoku Hormone Mfg. Co., Ltd.

Switched OTC drug of prescription drug, "ALTAT"

A histamine H₂-blocker "ALTAT" (active ingredient: Roxatidine Acetate Hydrochloride), having been developed and being manufactured and marketed by Teikoku Hormone, has been widely used for the treatment of gastric and duodenal ulcers since its launching in October 1986.

This is to inform that the OTC version of ALTAT will be newly launched by Kowa Shinyaku Company, Ltd. (Head Office: Nagoya, President: Yoshihiro Miwa) and Sato Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Seiichi Sato) as a digestive drug ("Switched OTC").

Roxatidine Acetate Hydrochloride has both potent inhibiting action of gastric acid and increasing action of gastric mucosa, and improves "stomachache, heartburn, dyspepsia and nausea," which are main uncomfortable symptoms of stomach.

The brand names of these products are "ALTAT-A" (Kowa Shinyaku) and "INOSEA ONE BLOCK" (Sato Pharmaceutical). They will be launched on May 9, 2005.